Weight loss pills for endometriosis is a topic that requires careful, evidence-based consideration. Endometriosis is a complex, oestrogen-dependent inflammatory condition that can affect body weight, metabolism, and energy levels — yet no weight loss medication has been specifically studied or licensed for use in this context. Hormonal treatments used to manage endometriosis may themselves influence weight, adding another layer of complexity. This article explores how endometriosis affects weight, which medications may be relevant, what the NHS recommends, and when to seek professional advice.

How Endometriosis Can Affect Weight and Metabolism

Endometriosis can affect weight through hormonal, inflammatory, and lifestyle mechanisms, though weight changes are not universal and individual experiences vary considerably.

Endometriosis is a chronic inflammatory condition in which tissue similar to the uterine lining grows outside the uterus, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum. Beyond its well-known effects on fertility and pelvic pain, endometriosis can have a meaningful impact on body weight and metabolic function, though the relationship is complex and not yet fully understood.

Endometriosis is an oestrogen-dependent condition: the hormonal environment associated with it may influence weight distribution and body composition, though the precise mechanisms remain an active area of research. Elevated levels of pro-inflammatory markers such as interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) have been observed in people with endometriosis; some researchers have proposed links to metabolic changes, but the evidence is heterogeneous and causation has not been established.

The chronic pain and fatigue that many people with endometriosis experience can significantly reduce physical activity levels, which may contribute to weight gain or difficulty losing weight over time.

Not sure if this is normal? Chat with one of our pharmacists →

It is important to note that weight changes in endometriosis are not universal. Some research suggests that people with the condition may have a lower body mass index (BMI) on average, while others experience weight gain. Individual experiences vary considerably, and any weight concerns should be assessed in the context of a person's overall health, symptoms, and treatment plan — ideally with support from a GP or specialist. The NHS and NICE NG73 (Endometriosis: diagnosis and management) provide authoritative guidance on the condition.

Are Weight Loss Pills Safe to Use With Endometriosis?

The question of whether weight loss pills are safe for people with endometriosis requires careful consideration. There is currently no NICE, NHS, or MHRA guidance specifically addressing the use of weight loss medications in the context of endometriosis. However, general UK licensing requirements, NICE technology appraisals, and individual product Summaries of Product Characteristics (SmPCs) all apply and should inform any prescribing decision.

Over-the-counter supplements — including herbal preparations, 'fat burners', and appetite suppressants — are largely unregulated in terms of clinical efficacy and safety. Many contain stimulants such as caffeine, synephrine, or green tea extract, which can exacerbate symptoms such as anxiety, palpitations, and gastrointestinal discomfort — all of which may already be heightened in people with endometriosis. Some supplements also contain phyto-oestrogenic compounds (e.g., soy isoflavones, red clover), which could theoretically influence oestrogen-sensitive tissue, though evidence for clinical harm in endometriosis remains limited. The MHRA advises against purchasing weight loss medicines or supplements from unregulated online sources, as these may be falsified, contaminated, or unlicensed. Only buy from registered UK pharmacies or retailers.

Prescription weight loss medications licensed in the UK include:

• Orlistat (a lipase inhibitor, available as Xenical on prescription or Alli at lower dose from pharmacies): licensed for adults with a BMI of 30 kg/m² or above, or 28 kg/m² or above in the presence of weight-related risk factors, alongside a reduced-calorie, low-fat diet. Per the SmPC and NICE guidance, treatment should be stopped after 12 weeks if the person has not lost at least 5% of their initial body weight.

• Semaglutide 2.4 mg (Wegovy, a GLP-1 receptor agonist): licensed for weight management under NICE TA875, which restricts its use to adults with a BMI of 35 kg/m² or above (or 30–34.9 kg/m² in certain circumstances) with at least one weight-related comorbidity. It is typically initiated within specialist NHS weight management services and is approved for time-limited use (up to two years under TA875 criteria). Important: semaglutide is contraindicated in pregnancy and breastfeeding. People who could become pregnant should use effective contraception during treatment and for at least two months after stopping semaglutide before attempting to conceive, in line with the SmPC.

Neither orlistat nor semaglutide has been specifically studied in people with endometriosis. Their use must be assessed individually, taking into account existing medications, hormonal therapies, and overall health status.

In summary, no weight loss pill can be considered universally safe for people with endometriosis without professional medical assessment. Self-medicating with unregulated supplements carries particular risks and is not recommended.

Medications That May Influence Weight in Endometriosis Treatment

Several endometriosis treatments — particularly DMPA and GnRH analogues — can cause weight gain or changes in body composition as recognised side effects.

Experiencing these side effects? Our pharmacists can help you navigate them →

Several medications commonly used to manage endometriosis can themselves influence body weight, which is an important consideration when addressing weight concerns in this population.

Hormonal therapies are the cornerstone of medical management for endometriosis (NICE NG73) and include:

• Combined oral contraceptive pills (COCPs): Some people report modest weight changes, though large clinical trials have not consistently confirmed a causal link.

• Progestogens: These include norethisterone, oral medroxyprogesterone acetate, depot medroxyprogesterone acetate (DMPA), and the levonorgestrel-releasing intrauterine system (LNG-IUS, e.g., Mirena). DMPA has the strongest evidence for weight gain among progestogens and may be less suitable where weight gain is a significant concern. Oral progestogens are associated with fluid retention and, in some individuals, increased appetite. Weight change with the LNG-IUS is variable and evidence for a consistent causal effect is limited.

• GnRH analogues (e.g., goserelin [Zoladex], leuprorelin [Prostap]): These induce a temporary menopausal state and are associated with changes in body composition, including increased fat mass and reduced lean muscle mass. A key concern with long-term use is bone mineral density loss; NICE NG73 recommends add-back hormonal therapy (e.g., low-dose oestrogen/progestogen) to mitigate this. Calcium and vitamin D supplementation may also be considered as clinically indicated.

• Dienogest (Visanne): A progestogen specifically licensed for endometriosis in the UK. Weight gain is listed as a common side effect in its SmPC.

Understanding that weight changes may be a side effect of treatment — rather than a failure of personal effort — is clinically important. People experiencing significant weight gain on hormonal therapy should discuss this with their prescriber, as alternative formulations or regimens may be available. Abruptly stopping prescribed medications to manage weight is not advised and could lead to a return of symptoms.

NHS-Recommended Approaches to Weight Management With Endometriosis

The NHS recommends a whole-diet approach, adapted physical activity, and psychological support for weight management in endometriosis, rather than weight loss pills or restrictive diets.

The NHS and NICE do not currently publish endometriosis-specific weight management guidelines, but general evidence-based principles of healthy weight management remain applicable and are supported by NICE guidance on obesity and the NHS Better Health and NHS Live Well programmes.

For people with endometriosis, a whole-diet approach is generally recommended over restrictive or fad diets. Some evidence suggests that a diet rich in omega-3 fatty acids (oily fish, flaxseed), fruits, vegetables, wholegrains, and legumes may help reduce systemic inflammation and support symptom management in some individuals, though the evidence base is limited and of variable quality. This should not replace medical treatment. Reducing intake of red meat, processed foods, trans fats, and refined sugars may also be beneficial. Where dietary changes are being considered, referral to a registered dietitian is advisable.

Physical activity is encouraged, though it must be adapted to individual pain levels and fatigue. Low-impact activities such as swimming, yoga, Pilates, and walking are often well tolerated and can support both weight management and mental wellbeing. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults; this target should be approached gradually in those with significant pain or fatigue. The NHS Live Well pages provide practical guidance on getting started.

Psychological support is also an important component of weight management in chronic illness. Endometriosis is associated with higher rates of anxiety and depression, which can affect eating behaviours and motivation. Referral to a dietitian or a structured NHS weight management programme may be appropriate for those who need additional support. Tier 2 and Tier 3 weight management services are available in many areas, typically for adults with a BMI above locally defined thresholds; your GP can advise on local referral pathways and eligibility criteria.

Risks and Interactions to Discuss With Your GP or Specialist

Key risks include herbal supplements reducing hormonal contraceptive efficacy, GLP-1 agonists worsening gastrointestinal symptoms, and orlistat impairing fat-soluble vitamin absorption.

Before considering any weight loss medication or supplement, people with endometriosis should have a thorough discussion with their GP or gynaecologist about potential risks and drug interactions. This is particularly important given the complexity of hormonal and anti-inflammatory treatments often used in this condition.

Key risks and interactions to be aware of include:

• Herbal supplements and hormonal therapies: St John's Wort induces liver enzymes (CYP450 pathway) and can significantly reduce the effectiveness of hormonal contraceptives and other medications, as documented in the BNF and relevant SmPCs. This could compromise endometriosis management and contraceptive efficacy.

• Stimulant-based supplements: Products containing high-dose caffeine, bitter orange (synephrine), or ephedrine-like compounds may worsen anxiety, disrupt sleep, and increase cardiovascular risk — concerns that are particularly relevant in people already managing chronic pain and fatigue.

• GLP-1 receptor agonists and gastrointestinal effects: Medications such as semaglutide commonly cause nausea, vomiting, and abdominal discomfort (per the Wegovy SmPC), which may be difficult to distinguish from, or may worsen, existing endometriosis-related gastrointestinal symptoms such as bloating and bowel pain. Severe vomiting or diarrhoea can also reduce the reliability of oral contraceptives; additional contraception should be used if this occurs.

• Orlistat and nutrient absorption: Orlistat reduces the absorption of fat-soluble vitamins (A, D, E, K). A multivitamin supplement should be taken daily, separated from orlistat by at least two hours (e.g., at bedtime). Orlistat also interacts with several other medicines: it should be taken at least four hours apart from levothyroxine, and it is not recommended for use with ciclosporin. People taking warfarin should have their INR monitored more closely, as orlistat may affect anticoagulant control. Refer to the BNF or the relevant SmPC for a full list of interactions.

• Bone health with GnRH analogues: The primary concern with GnRH analogue use is bone mineral density loss rather than vitamin D deficiency per se. NICE NG73 and BSGE guidance recommend add-back therapy and, where appropriate, calcium and vitamin D supplementation. Vitamin D status should be checked as clinically indicated.

Always disclose all supplements and over-the-counter products to your healthcare team. If you suspect you have experienced a side effect from any medicine or supplement, you can report it to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk). What appears to be a minor supplement can have clinically significant interactions with prescribed medications.

When to Seek Medical Advice About Weight and Endometriosis

Seek GP advice for unexplained weight changes, new or worsening bloating, suspected hormonal issues, or before starting any weight loss medication alongside endometriosis treatment.

Weight changes in the context of endometriosis can sometimes signal an underlying issue that warrants medical review. Knowing when to seek advice is an important aspect of self-management.

Contact your GP or specialist if you experience any of the following:

• Unexplained or rapid weight gain or loss that is not related to dietary changes or a new medication

• Significant bloating or abdominal distension that is new or worsening — this can occasionally indicate complications such as ovarian cysts or, rarely, other serious conditions, and should be assessed promptly

• Symptoms that may suggest a hormonal or thyroid issue, such as new or worsening fatigue, hair loss, mood changes, or irregular periods, alongside weight changes

• Side effects from current endometriosis medications that you believe are contributing to weight gain and are affecting your quality of life

• Interest in starting a prescription weight loss medication, to ensure it is appropriate and safe given your current treatment plan

Seek urgent medical attention — contact NHS 111 or attend your nearest A&E — if you experience:

• Severe or sudden-onset abdominal or pelvic pain

• Fever alongside abdominal pain

• Persistent vomiting

• Severe pain with a positive pregnancy test or suspected ectopic pregnancy

It is also worth seeking advice if weight concerns are affecting your mental health or your willingness to continue with prescribed endometriosis treatment. A GP can refer you to appropriate support services, including dietetics, physiotherapy, or psychological therapies available through the NHS.

Endometriosis UK (endometriosis-uk.org) provides resources and peer support for people navigating the broader health impacts of the condition, including guidance on lifestyle and wellbeing. The NHS Endometriosis page also offers reliable information on symptoms and when to get help. Managing weight with endometriosis is best approached as part of a holistic, medically supervised plan rather than through unsupported use of weight loss products.

Frequently Asked Questions